{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T22:48:19Z","timestamp":1784242099113,"version":"3.55.0"},"reference-count":51,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"\u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara","award":["FAR, ex-60%, 2022"],"award-info":[{"award-number":["FAR, ex-60%, 2022"]}]},{"name":"\u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara","award":["FAR, ex-60%, 2023"],"award-info":[{"award-number":["FAR, ex-60%, 2023"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Pseudomonas aeruginosa lung infections in cystic fibrosis (CF) patients represent a therapeutic challenge due to antibiotic resistance. Repurposing existing drugs is a promising approach for identifying new antimicrobials. A crucial factor in successful drug repurposing is using assay conditions that mirror the site of infection. Here, the impact of growth conditions on the anti-P. aeruginosa activity of a library of 3386 compounds was evaluated. To this, after 24 h exposure, the survival rate of CF P. aeruginosa RP73 planktonic cells was assessed spectrophotometrically under \u201cCF-like\u201d (artificial CF sputum, pH 6.8, 5% CO2) and enriched (Tryptone Soya Broth, pH 7.2, and aerobiosis) conditions. Among non-antibiotic compounds (n = 3127), 13.4% were active regardless of growth conditions, although only 3.2% had comparable activity; 4% and 6.2% were more active under CF-like or enriched conditions, respectively. Interestingly, 22.1% and 26.6% were active exclusively under CF-like and enriched conditions, respectively. Notably, 7 and 12 hits caused 100% killing under CF-like and enriched conditions, respectively. Among antibiotics (n = 234), 42.3% were active under both conditions, although only 18.4% showed comparable activity; 9.4% and 14.5% were more active under CF-like and enriched conditions, respectively. Interestingly, 23% and 16.6% were active exclusively under CF-like and enriched conditions, respectively. Sulphonamides showed higher activity under CF-like conditions, whereas tetracyclines, fluoroquinolones, and macrolides were more effective under enriched settings. Our findings indicated that growth conditions significantly affect the anti-P. aeruginosa activity of antibiotics and non-antibiotic drugs. Consequently, repurposing studies and susceptibility tests should be performed under physicochemical conditions that the pathogen tackles at the site of infection.<\/jats:p>","DOI":"10.3390\/antibiotics13070642","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T08:16:57Z","timestamp":1720772217000},"page":"642","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of Growth Conditions on High-Throughput Identification of Repurposing Drugs for Pseudomonas\u00a0aeruginosa Cystic Fibrosis Lung Infections"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5850-2810","authenticated-orcid":false,"given":"Giovanni","family":"Di Bonaventura","sequence":"first","affiliation":[{"name":"Department of Medical, Oral and Biotechnological Sciences, \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, 66100 Chieti, Italy"},{"name":"Center for Advanced Studies and Technology, \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Lupetti","sequence":"additional","affiliation":[{"name":"Department of Medical, Oral and Biotechnological Sciences, \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, 66100 Chieti, Italy"},{"name":"Center for Advanced Studies and Technology, \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6309-6981","authenticated-orcid":false,"given":"Arianna","family":"Pompilio","sequence":"additional","affiliation":[{"name":"Department of Medical, Oral and Biotechnological Sciences, \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, 66100 Chieti, Italy"},{"name":"Center for Advanced Studies and Technology, \u201cG. d\u2019Annunzio\u201d University of Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic fibrosis","volume":"397","author":"Shteinberg","year":"2021","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/jpids\/piac052","article-title":"Opportunistic pathogens in cystic fibrosis: Epidemiology and pathogenesis of lung infection","volume":"11","author":"Blanchard","year":"2022","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.4187\/respcare.08671","article-title":"The role of suboptimal concentrations of nebulized tobramycin in driving antimicrobial resistance in Pseudomonas aeruginosa isolates in cystic fibrosis","volume":"66","author":"Moore","year":"2021","journal-title":"Respir. Care"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Vitiello, A., Blasi, F., Sabbatucci, M., Zovi, A., Miele, F., Ponzo, A., Langella, R., and Boccellino, M. (2024). The Impact of Antimicrobial Resistance in Cystic Fibrosis. J. Clin. Med., 13.","DOI":"10.3390\/jcm13061711"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1067\/mcp.2001.115446","article-title":"Risks in new drug development: Approval success rates for investigational drugs","volume":"69","author":"DiMasi","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Barbarossa, A., Rosato, A., Corbo, F., Clodoveo, M.L., Fracchiolla, G., Carrieri, A., and Carocci, A. (2002). Non-antibiotic drug repositioning as an alternative antimicrobial approach. Antibiotics, 11.","DOI":"10.3390\/antibiotics11060816"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"106380","DOI":"10.1016\/j.ijantimicag.2021.106380","article-title":"Repositioning of non-antibiotic drugs as an alternative to microbial resistance: A systematic review","volume":"58","author":"Foletto","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.diagmicrobio.2009.09.009","article-title":"Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients","volume":"66","author":"King","year":"2010","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1128\/AEM.71.5.2501-2510.2005","article-title":"Application of a pH-sensitive fluoroprobe (C-SNARF-4) for pH microenvironment analysis in Pseudomonas aeruginosa biofilms","volume":"71","author":"Hunter","year":"2005","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0169-409X(02)00152-7","article-title":"Anaerobic metabolism and quorum sensing by Pseudomonas aeruginosa biofilms in chronically infected cystic fibrosis airways: Rethinking antibiotic treatment strategies and drug targets","volume":"54","author":"Hassett","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Morales, L.D., Av-Gay, Y., and Murphy, M.E.P. (2023). Acidic pH modulates Burkholderia cenocepacia antimicrobial susceptibility in the cystic fibrosis nutritional environment. Microbiol. Spectr., 11.","DOI":"10.1128\/spectrum.02731-23"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e21469","DOI":"10.1016\/j.heliyon.2023.e21469","article-title":"Effect of glucose on growth and co-culture of Staphylococcus aureus and Pseudomonas aeruginosa in artificial sputum medium","volume":"9","author":"Vasiljevs","year":"2023","journal-title":"Heliyon"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Moyne, O., Castelli, F., Bicout, D.J., Boccard, J., Camara, B., Cournoyer, B., Faudry, E., Terrier, S., Hannani, D., and Huot-Marchand, S. (2021). Metabotypes of Pseudomonas aeruginosa correlate with antibiotic resistance, virulence and clinical outcome in cystic fibrosis chronic infections. Metabolites, 11.","DOI":"10.3390\/metabo11020063"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Camus, L., Briaud, P., Vandenesch, F., and Moreau, K. (2021). How bacterial adaptation to cystic fibrosis environment shapes interactions between Pseudomonas aeruginosa and Staphylococcus aureus. Front. Microbiol., 12.","DOI":"10.3389\/fmicb.2021.617784"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jcf.2012.02.006","article-title":"Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis","volume":"11","author":"Hurley","year":"2012","journal-title":"J. Cyst. Fibros."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1378\/chest.123.5.1495","article-title":"Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: Lack of association in cystic fibrosis","volume":"123","author":"Smith","year":"2003","journal-title":"Chest"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1139\/m97-144","article-title":"Ceftazidime, gentamicin, and rifampicin, in combination, kill biofilms of mucoid Pseudomonas aeruginosa","volume":"43","author":"Ghani","year":"1997","journal-title":"Can. J. Microbiol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Aiyer, A., and Manos, J. (2022). The Use of Artificial Sputum Media to Enhance Investigation and Subsequent Treatment of Cystic Fibrosis Bacterial Infections. Microorganisms, 10.","DOI":"10.3390\/microorganisms10071269"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1099\/jmm.0.45969-0","article-title":"Microcolony formation: A novel biofilm model of Pseudomonas aeruginosa for the cystic fibrosis lung","volume":"54","author":"Sriramulu","year":"2005","journal-title":"J. Med. Microbiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1801297","DOI":"10.1183\/13993003.01297-2018","article-title":"Pathological mucus and impaired mucus clearance in cystic fibrosis patients result from increased concentration, not altered pH","volume":"52","author":"Hill","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1021\/acsbiomaterials.8b01054","article-title":"Mucus and Mucin Environments Reduce the Efficacy of Polymyxin and Fluoroquinolone Antibiotics against Pseudomonas aeruginosa","volume":"5","author":"Samad","year":"2019","journal-title":"ACS Biomater. Sci. Eng."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1021\/acsinfecdis.7b00238","article-title":"Sputum Active Polymyxin Lipopeptides: Activity against Cystic Fibrosis Pseudomonas aeruginosa Isolates and Their Interactions with Sputum Biomolecules","volume":"4","author":"Paulin","year":"2018","journal-title":"ACS Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1128\/AAC.00808-15","article-title":"Mucin Binding Reduces Colistin Antimicrobial Activity","volume":"59","author":"Huang","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1172\/JCI0213870","article-title":"Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients","volume":"109","author":"Worlitzsch","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1128\/AAC.01201-10","article-title":"Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus","volume":"55","author":"Lemaire","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1021\/pr200659h","article-title":"Proteomics of Pseudomonas aeruginosa Australian epidemic strain 1 (AES-1) cultured under conditions mimicking the cystic fibrosis lung reveals increased iron acquisition via the siderophore pyochelin","volume":"11","author":"Hare","year":"2012","journal-title":"J. Proteome Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1111\/1751-7915.14241","article-title":"Mechanisms of iron homeostasis in Pseudomonas aeruginosa and emerging therapeutics directed to disrupt this vital process","volume":"16","author":"Llamas","year":"2023","journal-title":"Microb. Biotechnol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1099\/jmm.0.019984-0","article-title":"Gene expression of Pseudomonas aeruginosa in a mucin-containing synthetic growth medium mimicking cystic fibrosis lung sputum","volume":"59","author":"Fung","year":"2010","journal-title":"J. Med. Microbiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1021\/acsinfecdis.3c00167","article-title":"Nutrient Limitation Sensitizes Pseudomonas aeruginosa to Vancomycin","volume":"9","author":"Chan","year":"2023","journal-title":"ACS Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1021\/mp500586p","article-title":"Novel Inhaled Combination Powder Containing Amorphous Colistin and Crystalline Rifapentine with Enhanced Antimicrobial Activities against Planktonic Cells and Biofilm of Pseudomonas aeruginosa for Respiratory Infections","volume":"12","author":"Zhou","year":"2015","journal-title":"Mol. Pharm."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e0164122","DOI":"10.1128\/aac.01641-22","article-title":"Colistin Enhances Rifampicin\u2019s Antimicrobial Action in Colistin-Resistant Pseudomonas aeruginosa Biofilms","volume":"67","author":"Armengol","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1111\/lam.13822","article-title":"Antibacterial and antibiofilm activities of fosfomycin combined with rifampin against carbapenem-resistant Pseudomonas aeruginosa","volume":"75","author":"Liu","year":"2022","journal-title":"Lett. Appl. Microbiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1093\/jac\/dkx296","article-title":"Rifampicin potentiation of aminoglycoside activity against cystic fibrosis isolates of Pseudomonas aeruginosa","volume":"72","author":"Mikalauskas","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"E5125","DOI":"10.1073\/pnas.1717525115","article-title":"Pseudomonas aeruginosa transcriptome during human infection","volume":"115","author":"Cornforth","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"117","DOI":"10.7150\/jca.3977","article-title":"Infectious diseases are analogous with cancer. Hypothesis and implications","volume":"3","author":"Benharroch","year":"2012","journal-title":"J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10585-008-9177-z","article-title":"Societal interactions in ovarian cancer metastasis: A quorum-sensing hypothesis","volume":"26","author":"Hickson","year":"2009","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.2174\/1568026616666160930131737","article-title":"Repurposing of anticancer drugs for the treatment of bacterial infections","volume":"17","author":"Soo","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1111\/1462-2920.12873","article-title":"Combatting bacterial infections by killing persister cells with mitomycin C","volume":"17","author":"Kwan","year":"2015","journal-title":"Environ. Microbiol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Jabarin, A., Shtar, G., Feinshtein, V., Mazuz, E., Shapira, B., Ben-Shabat, S., and Rokach, L. (2024). Eravacycline, an antibacterial drug, repurposed for pancreatic cancer therapy: Insights from a molecular-based deep learning model. Brief Bioinform., 25.","DOI":"10.1093\/bib\/bbae108"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Imperi, F., Fiscarelli, E.V., Visaggio, D., Leoni, L., and Visca, P. (2019). Activity and Impact on Resistance Development of Two Antivirulence Fluoropyrimidine Drugs in Pseudomonas aeruginosa. Front. Cell. Infect. Microbiol., 9.","DOI":"10.3389\/fcimb.2019.00049"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/1574-6968.12223","article-title":"The anticancer drug tirapazamine has antimicrobial activity against Escherichia coli, Staphylococcus aureus and Clostridium difficile","volume":"347","author":"Shah","year":"2013","journal-title":"FEMS Microbiol. Lett."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6047","DOI":"10.1021\/jm300123s","article-title":"Discovery and optimization of benzotriazine di-N-oxides targeting replicating and nonreplicating Mycobacterium tuberculosis","volume":"55","author":"Chopra","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Polmickait\u0117-Smirnova, E., \u0160arlauskas, J., Krik\u0161topaitis, K., Luk\u0161ien\u0117, \u017d., Staniulyt\u0117, Z., and Anusevi\u010dius, \u017d. (2020). Preliminary investigation of the antibacterial activity of antitumor drug 3-amino-1,2,4-benzotriazine-1,4-dioxide (tirapazamine) and its derivatives. Appl. Sci., 10.","DOI":"10.3390\/app10124062"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"10009","DOI":"10.1080\/07391102.2022.2151514","article-title":"Elucidating the function of hypothetical PE_PGRS45 protein of Mycobacterium tuberculosis as an oxido-reductase: A potential target for drug repurposing for the treatment of tuberculosis","volume":"41","author":"Medha","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jgar.2020.03.014","article-title":"Effects of caspofungin, tolcapone and other FDA-approved medications on MRSA susceptibility to vancomycin","volume":"22","author":"Moore","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1021\/acsnano.6b08731","article-title":"Tumor-penetrating nanoparticles for enhanced anticancer activity of combined photodynamic and hypoxia-activated therapy","volume":"11","author":"Wang","year":"2017","journal-title":"ACS Nano"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Peyclit, L., Baron, S.A., Hadjadj, L., and Rolain, J.M. (2022). In vitro screening of a 1280 FDA-approved drugs library against multidrug-resistant and extensively drug-resistant bacteria. Antibiotics, 11.","DOI":"10.3390\/antibiotics11030291"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/leu.2016.96","article-title":"A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells","volume":"30","author":"Das","year":"2016","journal-title":"Leukemia"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s12936-015-0720-5","article-title":"From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria","volume":"14","author":"Yalcin","year":"2015","journal-title":"Malar J."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Di Bonaventura, G., Lupetti, V., Di Giulio, A., Muzzi, M., Piccirilli, A., Cariani, L., and Pompilio, A. (2023). Repurposing High-Throughput Screening Identifies Unconventional Drugs with Antibacterial and Antibiofilm Activities against Pseudomonas aeruginosa under Experimental Conditions Relevant to Cystic Fibrosis. Microbiol. Spectr., 11.","DOI":"10.1128\/spectrum.00352-23"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1099\/mic.0.29175-0","article-title":"Sequence diversity of the mucABD locus in Pseudomonas aeruginosa isolates from patients with cystic fibrosis","volume":"152","author":"Bragonzi","year":"2006","journal-title":"Microbiology"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/7\/642\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:15:32Z","timestamp":1760109332000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/7\/642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,12]]},"references-count":51,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["antibiotics13070642"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics13070642","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,12]]}}}